logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
S

Stephen K. Brannan

independent consultant

33H-index
100Paper Count
8.5KCitation Count
Published Papers 46
Publication Date
logo
Effects of Xanomeline and Trospium Chloride for Negative Symptoms Associated With Physical Activity in Younger and Older Adults with Schizophrenia: Results From a 52-Week, Open-label Clinical Trial
errSchizophrenia Research
IF3.5
err2026-04-21
err0
PREAI
errPhilip D. Harvey; Inder Kaul; Soumya Chataverdi; Tej Patel; Amy Claxton; Colin Sauder; Cameron D. Harvey; Stephen K. Brannan; William P. Horan
errShare
errSave
Low incidence of extrapyramidal symptoms following treatment with a muscarinic agonist medication for schizophrenia
errSchizophrenia Research
IF3.5
err2026-03-12
err0
PREAI
errSteven D. Targum; Carolyn Watson; Amy Claxton; Pierre Nicolas; Keisha D. Novak; Inder Kaul; Stephen R. Marder; Wei-Chih Lin; William P. Horan; Ronald Marcus; Stephen K. Brannan
errShare
errSave
156: HEMODYNAMIC RESPONSIVENESS TO CRYSTALLOID VS ALBUMIN THERAPY DURING VA ECMO
errCritical Care Medicine
IF6
err2026-03-03
err0
PREAI
errSvoboda, Cora; Prucha, Jessica; Brannan, Stephen; Shostrom, Valerie; Olson, Logan
errShare
errSave
Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials (vol 11, 44, 2025)
errSCHIZOPHRENIA
IF4.1
err2025-03-18
err0
errOAAI
errKaul, Inder; Sawchak, Sharon; Claxton, Amy; Sauder, Colin; Hassman, Howard H.; Kakar, Rishi; Walling, David P.; Citrome, Leslie; Zhu, Haiyuan; Miller, Andrew C.; Brannan, Stephen K.
errShare
errSave
Towards Enhancing Drug Development Methodology to Treat Cognitive Impairment Associated With Schizophrenia and Other Neuropsychiatric Conditions: Insights From 2 Decades of Clinical Trials
errSCHIZOPHRENIA BULLETIN
IF4.8
err2025-02-21
err0
errOAAI
errHoran, William P.; Kalali, Amir; Brannan, Stephen K.; Drevets, Wayne; Leoni, Matthew; Mahableshwarkar, Atul; Martin, William J.; Rao, Srinivas; Reuteman-Fowler, Corey; Sauder, Colin; Savitz, Adam; Singh, Jaskaran; Tiller, Jane; Walker, Gary; Wendland, Jens R.; Harvey, Philip D.
errShare
errSave
EFFICACY OF KARXT ON NEGATIVE SYMPTOMS IN ACUTE SCHIZOPHRENIA: AN ANALYSIS OF POOLED DATA FROM 3 TRIALS
errINTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
IF3.7
err2025-02-12
err0
errOAAI
errVuocolo, Scott; Horan, William P.; Claxton, Amy; Targum, Steven D.; Kaul, Inder; Sawchak, Sharon; Miller, Andrew C.; Paul, Steven M.; Brannan, Stephen K.
errShare
errSave
SAFETY AND EFFICACY OF KARXT IN PATIENTS WITH SCHIZOPHRENIA IN THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EMERGENT TRIALS
errINTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
IF3.7
err2025-02-12
err0
errOAAI
errKramer, Kenneth; Brannan, Stephen K.; Sauder, Colin; Kaul, Inder
errShare
errSave
Methods to address functional unblinding of raters in CNS trials
errTRANSLATIONAL PSYCHIATRY
IF6.2
err2025-02-07
err0
errOAAI
errTargum, Steven D.; Horan, William P.; Davis, Vicki G.; Breier, Alan; Brannan, Stephen K.
errShare
errSave
Capturing changes in social functioning and positive affect using ecological momentary assessment during a 12-month trial of xanomeline and trospium chloride in schizophrenia
errSCHIZOPHRENIA RESEARCH
IF3.5
err2025-02-01
err0
PREAI
errHarvey, Philip D.; Kaul, Inder; Chataverdi, Soumya; Patel, Tej; Claxton, Amy; Sauder, Colin; Saber, John N.; Brannan, Stephen K.; Horan, William P.
errShare
errSave
Response to Commentaries
errSCHIZOPHRENIA BULLETIN
IF4.8
err2025-01-25
err0
errOAAI
errHoran, William P.; Kalali, Amir; Brannan, Stephen K.; Drevets, Wayne; Mahableshwarkar, Atul; Rao, Srinivas; Reuteman-Fowler, Corey; Savitz, Adam; Singh, Jaskaran; Walker, Gary; Wendland, Jens R.; Harvey, Philip D.
errShare
errSave
Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials
errSCHIZOPHRENIA RESEARCH
IF3.5
err2024-12-01
err17
errOAAI
errHoran, William P.; Targum, Steven D.; Claxton, Amy; Kaul, Inder; Yohn, Samantha E.; Marder, Stephen R.; Miller, Andrew C.; Brannan, Stephen K.
errShare
errSave
Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials
errSCHIZOPHRENIA
IF4.1
err2024-11-02
err6
errOAAI
errKaul, Inder; Sawchak, Sharon; Claxton, Amy; Sauder, Colin; Hassman, Howard H.; Kakar, Rishi; Walling, David P.; Citrome, Leslie; Zhu, Haiyuan; Miller, Andrew C.; Brannan, Stephen K.
errShare
errSave
The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia
errFRONTIERS IN PSYCHIATRY
IF3.2
err2024-10-04
err5
errOAAI
errYohn, Samantha E.; Harvey, Phillip D.; Brannan, Stephen K.; Horan, William P.
errShare
errSave
Muscarinic Receptor Activators as Novel Treatments for Schizophrenia
errBIOLOGICAL PSYCHIATRY
IF9
err2024-10-01
err8
errOAAI
errPaul, Steven M.; Yohn, Samantha E.; Brannan, Stephen K.; Neugebauer, Nichole M.; Breier, Alan
errShare
errSave
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial
errLANCET
IF88.5
err2024-01-01
err46
PREAI
errKaul, Inder; Sawchak, Sharon; Correll, Christoph U.; Kakar, Rishi; Breier, Alan; Zhu, Haiyuan; Miller, Andrew C.; Paul, Steven M.; Brannan, Stephen K.
errShare
errSave
ASSESS THE IMPACT OF SHOCK INDEX AS A PROGNOSTICATOR OF POST-INTUBATION HYPOTENSION
errCRITICAL CARE MEDICINE
IF6
err2023-12-14
err0
errOAAI
errBallard, Rachel; Brannan, Stephen; Peitz, Greg; Coleman, Scott
errShare
errSave
166: COMPARISON OF DOSING STRATEGIES OF HYDROXOCOBALAMIN FOR VASOPLEGIC SYNDROME AFTER CARDIAC SURGERY
errCRITICAL CARE MEDICINE
IF6
err2023-12-14
err0
errOAAI
errBuenger, Bailey; Behlers, Quinton; Brannan, Stephen; Peitz, Gregory
errShare
errSave
Safety and efficacy of KarXT (Xanomeline Trospium) in Schizophrenia in the Phase 3, Randomized, Double-Blind, Placebo-Controlled EMERGENT-2 Trial
errCNS SPECTRUMS
IF4.1
err2023-04-14
err3
errOAAI
errCorrell, Christoph U.; Miller, Andrew C.; Sawchak, Sharon; Kaul, Inder; Paul, Steven M.; Brannan, Stephen K.
errShare
errSave
Evidence of trospium's ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results
errPSYCHOPHARMACOLOGY
IF3.3
err2023-04-10
err37
errOAAI
errBreier, Alan; Brannan, Stephen K.; Paul, Steven M.; Miller, Andrew C.
errShare
errSave
Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia
errSCHIZOPHRENIA
IF4.1
err2022-12-03
err40
errOAAI
errCorrell, Christoph U.; Angelov, Angel S.; Miller, Andrew C.; Weiden, Peter J.; Brannan, Stephen K.
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
L
Lenore J. Launer
H-index: 181 · Papers: 1.4K
D
Dennis S. Charney
H-index: 177 · Papers: 816
L
Lewis H. Kuller
H-index: 172 · Papers: 1.4K
C
Charles B. Nemeroff
H-index: 167 · Papers: 2.4K
A
A. John Rush
H-index: 163 · Papers: 1.2K
View more